NSCLC Stage IV Clinical Trials

104 clinical trials for NSCLC Stage IV across international registries, including 22 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC — RECRUITING · PHASE1
• Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In — RECRUITING · PHASE3
• A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC — RECRUITING · PHASE1
• Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC — RECRUITING · PHASE2
• A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) — RECRUITING · PHASE2
• TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50% — RECRUITING
• A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy — RECRUITING · PHASE2
• Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC — RECRUITING · PHASE1
• A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer — RECRUITING · NA
• Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC — RECRUITING · PHASE2
• Outpatient Pulmonary Rehabilitation in Non-small-cell Lung Cancer Receiving Immunotherapy — RECRUITING · NA
• Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations — RECRUITING
• Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases — RECRUITING · PHASE2
• Lung Cancer Registry — RECRUITING
• Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG) — RECRUITING · PHASE2
• AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer — RECRUITING
• Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer — RECRUITING · PHASE3
• Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis — RECRUITING · PHASE2
• Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis — RECRUITING · PHASE2
• ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer — RECRUITING
• Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC — RECRUITING
• Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer — RECRUITING · PHASE2
• Plasma-Adapted First-Line Pembro In NSCLC — ACTIVE_NOT_RECRUITING · PHASE2
• Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC — ACTIVE_NOT_RECRUITING · PHASE2
• Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status — ACTIVE_NOT_RECRUITING · PHASE2
• A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies — COMPLETED · PHASE2
• 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC — COMPLETED · NA
• Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung — ACTIVE_NOT_RECRUITING · PHASE2
• Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients — ACTIVE_NOT_RECRUITING · PHASE2
• A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) — COMPLETED · PHASE2
• Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg — NOT_YET_RECRUITING · PHASE2
• Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC — NOT_YET_RECRUITING · PHASE1
• Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer — TERMINATED · PHASE1
• Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC — TERMINATED · PHASE2
• Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) — COMPLETED · PHASE2
• 1st Line Durvalumab in PS 2 NSCLC Patients — ACTIVE_NOT_RECRUITING · PHASE2
• A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients — ACTIVE_NOT_RECRUITING · PHASE2
• Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma — COMPLETED · PHASE1
• Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC — TERMINATED · PHASE2
• Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer — TERMINATED · PHASE2
• A Study to Investigate LYL797 in Adults With Solid Tumors — TERMINATED · PHASE1
• A Biomarker Screening Protocol for Participants With Solid Tumors — TERMINATED
• Phase 2 Study of Dacomitinib in NSCLC — ACTIVE_NOT_RECRUITING · PHASE2
• SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors — OTHER · PHASE2
• AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002) — COMPLETED · PHASE2
• Primary Tumor Resection With EGFR TKI for Stage IV NSCLC — ACTIVE_NOT_RECRUITING · PHASE2
• IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study — TERMINATED · PHASE2
• Cancer Patient Remote Monitoring for Timely Communication Study — NOT_YET_RECRUITING
• SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs — COMPLETED · PHASE2
• Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project) — OTHER

Refine this search